---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-24-000091"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:36:12.152035+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD

## Summary
- Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.
- AVISE CTD trailing twelve-month ASP $404, up 26% from $320 a year ago.
- Net loss first nine months 2024 improved 37% to $11.4M from $18.1M; adj. EBITDA loss improved 42% to $7.6M.
- Cash and equivalents $22.0M at Sept 30; net cash burn $2.5M in Q3.
- Completed validation for new biomarkers, submitted to NY State; appointed Jeff Black as CFO effective Sept 1.

## SEC filing metadata
- accession: 0001274737-24-000091
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473724000091/0001274737-24-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473724000091/exdx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-24-000091
- JSON: https://secwatch.observer/filing/0001274737-24-000091.json
- Plain text: https://secwatch.observer/filing/0001274737-24-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.